1 February 2024
Medannex strengthens its board ahead of clinical expansion
Medannex announced today that Sir Graham Brady has been appointed as a non-executive director of the company as of 1 February 2024.
Currently a Member of Parliament at Westminster, Sir Graham has had a remarkable political career, having held a range of senior positions. The post for which he is perhaps best known is as the longstanding Chair of the 1922 Committee. He will stand down as an MP at the next general election and plans to devote his time to helping the growth of British business. Sir Graham brings a wealth of experience to Medannex as the company embarks on an ambitious programme of clinical trials.
Sir Graham said: “I am delighted to be joining the team of this young and exciting life sciences company. Medannex has won awards for its pioneering work in areas of unmet medical need and I look forward to being an active part of its continued progress. The UK is looking to companies like Medannex for the next phase of our country’s growth.”
Professor Christopher Wood, Medannex’s Chairman, added: “It’s a real pleasure to welcome Sir Graham to the board of directors of Medannex. He adds a new and important dimension to the company in its quest to develop new treatments for cancer and autoimmune diseases.”
Medannex has a new, first-in-class medicine (MDX-124) currently undergoing clinical trials at three major cancer centres in the UK. MDX-124 has the potential to offer significant clinical benefit in the treatment of many cancers – including pancreas, triple-negative breast, colorectal and lung – as well as autoimmune diseases such as multiple sclerosis, systemic lupus and rheumatoid arthritis. MDX-124 also has potential as a treatment for certain childhood cancers, an opportunity that the company is exploring in the UK and the USA.
Medannex CEO Ian Abercrombie said: ”In Medannex, we are developing a new treatment with huge potential, and with a magnificent and dedicated team to make it happen. The addition of a board member with the stature of Sir Graham Brady is a tremendous encouragement to the team and our shareholders.”